Cart
sales@molnova.com
Crizanlizumab
CAS No. 1690318-25-2
Crizanlizumab( —— )
Catalog No. M36878 CAS No. 1690318-25-2
Crizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 748 | In Stock |
|
| 10MG | 1254 | In Stock |
|
| 25MG | 1862 | In Stock |
|
| 50MG | 2465 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCrizanlizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionCrizanlizumab (Adakveo) is a humanized monoclonal antibody against P-selectin for the prevention of pain crises in sickle cell disease.
-
DescriptionCrizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1690318-25-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020).
molnova catalog
related products
-
YD23
YD23 is a PROTAC that induces SMARCA2 degradation, has anticancer activity, and selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro.
-
TRAP-14 amide
TRAP-14 amide
-
SRI-37330
SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production, and reverses hepatic steatosis.
